Company Encyclopedia
View More
name
HWHG
600079.SH
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injection, a narcotic analgesic; remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery; and mifepristone preparations for pregnancy prevention or termination. It also provides zuka wood particles for colds and cough; compound muniziqi granules to treat skin and gynecological diseases; urokinase injection for thromboembolic diseases; and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals.
3.165 T
600079.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking82/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.77%B
    • Profit Margin5.91%B
    • Gross Margin47.61%B
  • Growth ScoreD
    • Revenue YoY-5.40%D
    • Net Profit YoY-26.94%D
    • Total Assets YoY-1.40%D
    • Net Assets YoY4.19%C
  • Cash ScoreC
    • Cash Flow Margin1692.22%B
    • OCF YoY-5.40%D
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreC
    • Gearing Ratio40.53%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HWHG: Pregabalin sustained-release tablets have received the drug clinical trial approval notice

    HWHG's subsidiary Yichang HWHG Pharmaceutical recently received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration for Pregabalin Sustained-Release Tablets. This medication is primarily used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. This application aims to add new indications and expand its clinical use

    Zhitong·
    SH
    600079
    -4.16%
    Zhitong·
    SH
    600079
    -4.16%

    HWHG: Shareholders holding more than 5% of shares have completed the commitment to acquire Wuhu Xinfeng's stake

    HWHG announced that, after the approval of the third extraordinary general meeting of shareholders in 2025, the commitment change related to the acquisition of Wuhu Xinfeng's shares by Yichang Chantuo, a shareholder holding more than 5%. Recently, the company received a letter stating that Yichang Chantuo designated its wholly-owned subsidiary, Yichang State-owned Capital Investment Holding Group Co., Ltd., to complete the acquisition and delivery of all shares of Wuhu Xinfeng held by China Cinda and Xinshi Li Bao on October 29. After the acquisition is completed, Yichang Chantuo will hold all shares through its subsidiary, achieving complete control over Wuhu Xinfeng, and the relevant commitments will be fulfilled

    Zhitong·
    SH
    600079
    -4.16%
    Zhitong·
    SH
    600079
    -4.16%

    HWHG: Dapoxetine Hydrochloride Tablets have obtained the drug registration certificate

    HWHG's subsidiary Jiulong HWHG recently obtained the drug registration certificate for Dapoxetine Hydrochloride Tablets approved by the National Medical Products Administration. This drug is used to treat male premature ejaculation. Jiulong HWHG submitted the marketing authorization application in July 2024, with research and development investment of approximately 10 million yuan, and production entrusted to Chongqing Boteng Pharmaceutical Co., Ltd. The national sales are expected to be around 1.1 billion yuan in 2024, with major competitors including Shandong Huabokai Sheng Biotechnology Co., Ltd. and others

    Zhitong·
    SH
    600079
    -4.16%
    Zhitong·
    SH
    600079
    -4.16%

    HWHG: Oxcarbazepine extended-release tablets received a tentative approval number from the U.S. FDA

    According to the Zhitong Finance APP, HWHG announced that its holding subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd. (referred to as "Renfulikang"), has received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine Extended-Release Tablets. Oxcarbazepine Extended-Release Tablets are used to treat partial seizures in patients aged 6 years and older with epilepsy

    Zhitong·
    SH
    600079
    -4.16%
    Zhitong·
    SH
    600079
    -4.16%

    HWHG: Flurbiprofen Ester Injection has obtained a drug registration certificate

    HWHG's subsidiary Yichang HWHG Pharmaceutical recently obtained the "Drug Registration Certificate" for Fluorobiphenyl Ester Injection approved by the National Medical Products Administration. This drug is a non-steroidal analgesic, suitable for postoperative and cancer pain relief. Its approval will enrich the company's product line and have a positive impact on the company

    Zhitong·
    SH
    600079
    -4.16%
    Zhitong·
    SH
    600079
    -4.16%
    © 2025 Longbridge｜Disclaimer